智通财经APP讯，生物股份(600201.SH)发布公告，近日，公司全资子公司金宇保灵生物药品有限公司(简称“金宇保灵”)收到了农业农村部颁发的猫传染性腹膜炎mRNA疫苗临床试验批件(批件号：2025062)。
猫传染性腹膜炎mRNA疫苗属于新型创新疫苗，公司率先攻克抗原设计及核酸疫苗产业化难点，成为全国首家获得猫传染性腹膜炎兽用核酸疫苗临床批件的公司，为公司后续兽用核酸疫苗发展奠定基础。兽用疫苗产品从前期研发到上市销售整个周期较长，项目研究开发进度、技术成果、后期产业化应用进程等尚存在一定不确定性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.